Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Cohen

Family Medicine Delray Beach, FL Doctor of Osteopathy

NPI 1083687610 CMS profile 321544

15300 Jog Rd, Suite 205, Delray Beach, FL 33446

Open in the dashboard

General payments

$1,758

97 records reported · program years 2019–2025

Research payments

$1,554

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$630,613 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Robert Cohen of Delray Beach, FL is reported in the CMS Open Payments database as having received $1,758 across 97 general payments and $1,554 in research payments paid to them. Separately, studies naming them as principal investigator received $630,613 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25 1
2024 General $56 2
2023 General $503 26
2023 Research $300 1
2022 General $617 35
2022 Research $300 1
2021 General $110 6
2021 Research $954 1
2020 General $74 5
2019 General $374 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Cohen
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Robert Cohen were reported at $25. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Robert Cohen Family Medicine median Middle half National median
2019 $374 $150 $41–$543 $163
2020 $74 $120 $32–$415 $114
2021 $110 $137 $35–$551 $132
2022 $617 $137 $37–$512 $149
2023 $503 $149 $42–$545 $160
2024 $56 $156 $44–$560 $164
2025 $25 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $192 12 payments
  2. Amarin Pharma Inc. $159 9 payments
  3. Almatica Pharma LLC $152 7 payments
  4. Pfizer Inc. $151 9 payments
  5. Exact Sciences Corporation $128 6 payments
  6. Amgen Inc. $113 7 payments
  7. GlaxoSmithKline, LLC. $79 5 payments
  8. AbbVie, Inc. $70 4 payments
  9. Otsuka America Pharmaceutical, Inc. $67 3 payments
  10. Novartis Pharmaceuticals Corporation $66 4 payments
  11. Other $580 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,758 97 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $173 11 payments
  2. Ozempic $154 10 payments
  3. LOREEV XR $152 7 payments
  4. Cologuard Collection Kit $128 6 payments
  5. GRALISE $96 5 payments
  6. Vascepa Cardiovascular $89 5 payments
  7. Repatha $82 5 payments
  8. SHINGRIX $79 5 payments
  9. SERTRALINE HCL $78 4 payments
  10. Vascepa Hypertriglyceridemia $70 4 payments
  11. Other $1,576 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,554 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

1,980

Median for Family Practice: 1,826

Drug cost

$39,416

Median for Family Practice: $120,094

Branded share of claims

6.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $16,662
Levothyroxine Sodium Generic 225 $2,127
Synthroid Levothyroxine Sodium Brand 24 $1,987
Atorvastatin Calcium Generic 180 $1,861
Silodosin Generic 11 $1,553
Rosuvastatin Calcium Generic 100 $1,191
Losartan Potassium Generic 96 $1,035
Simvastatin Generic 130 $985
Albuterol Sulfate Hfa Albuterol Sulfate Brand 21 $853
Omeprazole Generic 85 $779

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOREEV XR
  • Almatica Pharma LLC $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record